GILD Gilead Sciences News . The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. ... Gilead Sciences (NASDAQ:GILD) Historical Stock Chart From Aug 2020 to Sep 2020 Gilead Sciences (NASDAQ:GILD) Historical Stock Chart From Sep 2019 to Sep 2020 Latest GILD Messages
The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners.
Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Earlier this year, Gilead Sciences (NASDAQ:GILD) paid almost $5 billion to acquire the … Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 33.59%. Gilead Sciences employs 11,800 workers across the globe.Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. One share of GILD stock can currently be purchased for approximately $64.51.Gilead Sciences has a market capitalization of $80.88 billion and generates $22.45 billion in revenue each year. Since then, GILD stock has decreased by 12.5% and is now trading at $64.51.
© American Consumer News, LLC dba MarketBeat® 2010-2020. Gilead Sciences announced a quarterly dividend on Thursday, July 30th.
The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. Gilead now has several studies showing a benefit for remdesivir in coronavirus treatment. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.
Trillium's CD47 pipeline has enormous commercial potential as cutting-edge treatments for both solid tumors and blood cancers. Learn about financial terms, types of investments, trading strategies and more.MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; and insitro Inc.
66.71-0.08 (-0.12%) Upgrade to Real-Time Premarket . Pfizer, for its part, has a well-documented history of buying novel cancer assets at a sky-high premium.
Export data to Excel for your own analysis. With a one year PEG ratio of 337.48, Gilead Sciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 90.04% of US stocks. Approximately 1.6% of the shares of the company are sold short. The company provided EPS guidance of $6.25-7.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.69.
On average, they expect Gilead Sciences' share price to reach $78.31 in the next year. The biopharmaceutical company had revenue of $5.14 billion for the quarter, compared to analysts' expectations of $5.24 billion.
Is Trillium's stock still a buy after this hefty jump? Retirement "Gilead Sciences' stock is owned by a variety of retail and institutional investors. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Investors of record on Tuesday, September 15th will be paid a dividend of $0.68 per share on Tuesday, September 29th. GILD has a market capitalization of $82,758,345,664 -- more than approximately 97.66% of US stocks.
PEG Ratios above 1 indicate that a company could be overvalued.Gilead Sciences has a P/B Ratio of 3.60.
Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Get daily stock ideas top-performing Wall Street analysts. Please log in to your account or sign up in order to add this asset to your watchlist.